Using our proprietary EEVâ„¢ platform, we are creating a diverse and expanding pipeline of oligonucleotide, antibody and enzyme-based programs. Our lead programs are in neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). Our modular approach supports efficient expansion of development into multiple therapeutic areas, including immunology, oncology and metabolic diseases.
ENTR-601-44 (Exon 44 Skipping Oligonucleotide)
Neuromuscular Disease : Duchenne Muscular Dystrophy
|
|
|
|
|
|
Preclinical
|
Exon 45 Skipping Oligonucleotide
Neuromuscular Disease : Duchenne Muscular Dystrophy
|
|
|
|
|
|
Preclinical
|
Additional Exons
Neuromuscular Disease : Duchenne Muscular Dystrophy
|
|
|
|
|
|
Discovery
|
ENTR-701 CUG Steric Blocker Oligonucleotide
Neuromuscular Disease : Myotonic Dystrophy Type 1
|
|
|
|
|
|
Preclinical
|
GYS1 Knockdown Oligonucleotide
Neuromuscular Disease : Pompe
|
|
|
|
|
|
Preclinical
|
|
|
CD33 Exon 2 Skipping Oligonucleotide
Neurodegenerative Diseases
|
|
|
|
|
|
Preclinical
|
|
|
IRF5 Knockdown Oligonucleotide
Inflammatory Diseases
|
|
|
|
|
|
Preclinical
|
|
|
β-catenin Degrader Antibody
Solid Tumors
|
|
|
|
|
|
Discovery
|
Note: In 2020, we announced that we are exploring partnership opportunities to continue the development of ENTR-501 Enzyme Replacement.
